MCID: ESP002
MIFTS: 50

Esophageal Varix

Categories: Cardiovascular diseases, Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Esophageal Varix

MalaCards integrated aliases for Esophageal Varix:

Name: Esophageal Varix 11 28 14
Esophageal Varices 11 19 75 53 14 16
Bleeding Esophageal Varices 11 53 71
Esophageal Varices in Disease Classified Elsewhere, with Bleeding 11
Esophageal Varices with Bleeding in Disease Ec 11
Esophageal Varices Without Mention of Bleeding 11
Esophageal Varices Without Bleeding 11
Esophageal Varices with Bleeding 11
Bleeding Oesophageal Varices 11

Classifications:



External Ids:

Disease Ontology 11 DOID:112
ICD9CM 34 456.0 456.2 456.20
NCIt 49 C78282
UMLS 71 C0155789 C0155791 C0155792

Summaries for Esophageal Varix

MalaCards based summary: Esophageal Varix, also known as esophageal varices, is related to fatty liver disease and non-alcoholic fatty liver disease. An important gene associated with Esophageal Varix is SST (Somatostatin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Defects of contact activation system (CAS) and kallikrein/kinin system (KKS). The drugs Ethiodized oil and Ethanolamine oleate have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and kidney, and related phenotypes are homeostasis/metabolism and liver/biliary system

Wikipedia: 75 Esophageal varices are extremely dilated sub-mucosal veins in the lower third of the esophagus. They are... more...

Related Diseases for Esophageal Varix

Diseases related to Esophageal Varix via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 772)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 31.8 INS GPT CRP AFP
2 non-alcoholic fatty liver disease 31.5 INS HP GPT CRP ALB
3 schistosomiasis 30.9 GPT F2 CRP ALB
4 alcoholic liver cirrhosis 30.8 INS GPT F2 ALB AFP
5 varicose veins 30.8 SERPINC1 LGALS3BP LGALS3 F2
6 thrombophilia due to thrombin defect 30.7 SERPINC1 F3 F2
7 splenic artery aneurysm 30.6 F2 ATP4A ATP12A
8 peptic esophagitis 30.5 ATP4A ATP12A ALB
9 polycystic liver disease 30.4 SST SERPINA1 PKHD1 ALB
10 peliosis hepatis 30.4 GPT F2 ALB AFP
11 arteriovenous malformation 30.4 F3 F2 ALB
12 portal vein thrombosis 30.4 THPO SERPINC1 GPT F3 F2 CRP
13 pleural empyema 30.4 GPT F2 CRP ALB
14 disseminated intravascular coagulation 30.3 SERPINC1 GPT F3 F2 CRP
15 hepatic coma 30.3 SERPINC1 GPT F3 F2 ATP12A ALB
16 cholestasis 30.3 SERPINA1 GPT F2 CP
17 polycythemia 30.3 THPO F3 F2 CRP
18 alcoholic hepatitis 30.3 GPT F2 CRP ALB
19 toxic shock syndrome 30.3 SERPINC1 F3 CRP
20 biliary atresia 30.3 GPT F2 ALB
21 dieulafoy lesion 30.3 F2 ATP4A ATP12A
22 hepatorenal syndrome 30.3 GPT F2 BMAL2 ALB AFP
23 bile reflux 30.3 ATP4A ATP12A ALB
24 pneumonia 30.2 SERPINA1 GPT CRP ALB
25 hepatic encephalopathy 30.2 SST GPT F2 ALB
26 aortic aneurysm 30.2 F3 F2 CRP ALB
27 autosomal dominant polycystic kidney disease 30.2 SST PKHD1 CRP ALB
28 klippel-trenaunay-weber syndrome 30.2 SST SERPINC1 F2
29 hepatitis b 30.2 GPT F2 ALB AFP
30 lung abscess 30.2 GPT CRP ALB
31 cavernous hemangioma 30.2 SERPINC1 F3 F2 ALB AFP
32 antithrombin iii deficiency 30.2 SERPINC1 F3 F2
33 microinvasive gastric cancer 30.2 ATP4A ATP12A AFP
34 esophageal atresia 30.2 SST ATP4A ATP12A
35 factor vii deficiency 30.2 SERPINC1 F3 F2
36 septic arthritis 30.2 GPT CRP ALB
37 protein s deficiency 30.2 SERPINC1 F3 F2
38 diarrhea 30.2 SST SERPINA1 GPT ALB
39 hernia, hiatus 30.2 INS CRP ATP4A ATP12A ALB
40 lymph node tuberculosis 30.2 CRP ALB
41 portal hypertension 30.2 THPO SST PKHD1 GPT F2 ALB
42 wilson disease 30.2 SERPINA1 GPT F2 CP ALB
43 hepatic veno-occlusive disease 30.1 THPO SERPINC1 F3
44 constrictive pericarditis 30.1 SERPINA1 CRP ALB
45 behcet syndrome 30.1 SERPINC1 F3 F2 CRP CP ALB
46 graves disease 1 30.1 INS CRP ALB
47 polycythemia vera 30.1 THPO SERPINC1 F3 F2 CRP
48 factor viii deficiency 30.1 SERPINC1 SERPINA1 F3 F2 ALB
49 nutritional deficiency disease 30.1 F2 CRP CP ATP4A ATP12A ALB
50 hypersplenism 30.1 THPO SERPINC1 PKHD1 GPT F3 F2

Comorbidity relations with Esophageal Varix via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Esophageal Disease Esophagitis
Heart Disease Hepatic Encephalopathy
Portal Hypertension

Graphical network of the top 20 diseases related to Esophageal Varix:



Diseases related to Esophageal Varix

Symptoms & Phenotypes for Esophageal Varix

GenomeRNAi Phenotypes related to Esophageal Varix according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 AFP ALB ATP12A ATP4A BMAL2 CP
2 no effect GR00402-S-2 10.18 ALB ATP12A ATP4A BMAL2 CP CRP

MGI Mouse Phenotypes related to Esophageal Varix:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.06 AFP ALB ATP12A ATP4A CP CRP
2 liver/biliary system MP:0005370 9.86 AFP ALB CP HP INS LGALS3
3 digestive/alimentary MP:0005381 9.56 ALB ATP12A ATP4A F2 INS LGALS3
4 immune system MP:0005387 9.5 ALB ATP4A CP CRP F2 F3

Drugs & Therapeutics for Esophageal Varix

Drugs for Esophageal Varix (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
2
Ethanolamine oleate Approved Phase 4 2272-11-9
3
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
4
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
5
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
6
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
7 Pharmaceutical Solutions Phase 4
8 Vasoconstrictor Agents Phase 4
9 Retinol palmitate Phase 4
10 Hormone Antagonists Phase 4
11 Proton Pump Inhibitors Phase 4
12 Antineoplastic Agents, Hormonal Phase 4
13 Gastrointestinal Agents Phase 4
14
Rifaximin Approved, Investigational Phase 2, Phase 3 80621-81-4 46783403 6436173
15
Warfarin Approved Phase 3 81-81-2, 129-06-6 54678486
16
Simvastatin Approved Phase 3 79902-63-9 54454
17
Nitric Oxide Approved Phase 3 10102-43-9 145068
18
Carvedilol Approved, Investigational Phase 2, Phase 3 72956-09-3 2585
19
Propranolol Approved, Investigational Phase 3 318-98-9, 525-66-6 62882 4946
20
Nadolol Approved Phase 3 42200-33-9 39147
21
Vapreotide Experimental, Investigational Phase 3 103222-11-3 23725064 70689318 71306
22 Anti-Bacterial Agents Phase 2, Phase 3
23 Anti-Infective Agents Phase 2, Phase 3
24 Sclerosing Solutions Phase 3
25 Anticoagulants Phase 3
26 Fibrin Tissue Adhesive Phase 3
27 Hemostatics Phase 3
28 Coagulants Phase 3
29 Antimetabolites Phase 3
30 Hypolipidemic Agents Phase 3
31 Anticholesteremic Agents Phase 3
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
33 Lipid Regulating Agents Phase 3
34 Analgesics Phase 3
35
Ulipristal acetate Phase 3 126784-99-4 13559282 130904
36 Antihypertensive Agents Phase 2, Phase 3
37 Adrenergic alpha-Antagonists Phase 2, Phase 3
38 Adrenergic alpha-1 Receptor Antagonists Phase 2, Phase 3
39 Hormones Phase 2, Phase 3
40 Calcium, Dietary Phase 2, Phase 3
41 calcium channel blockers Phase 2, Phase 3
42 Antioxidants Phase 2, Phase 3
43 Protective Agents Phase 2, Phase 3
44 Neurotransmitter Agents Phase 3
45 Adrenergic beta-Antagonists Phase 3
46 Adrenergic Antagonists Phase 3
47 Adrenergic Agents Phase 3
48 Anti-Arrhythmia Agents Phase 3
49 Vasodilator Agents Phase 3
50
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Impact of Nonselective Beta-blocker on Acute Kidney Injury in Cirrhotic Patients With Esophageal Varices Unknown status NCT04074473 Phase 4 propranolol
2 Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices Unknown status NCT02740166 Phase 4 propranolol
3 Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection Completed NCT00799851 Phase 4 cyanoacrylate injection
4 Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices: A Randomized, Placebo-controlled Multicenter Trial Completed NCT02119884 Phase 4 Terlipressin;Octreotide
5 Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices Completed NCT00534677 Phase 4 Terlipressin;Octreotide
6 PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL Completed NCT01893541 Phase 4 PROPRANOLOL
7 Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices Completed NCT01291277 Phase 4
8 Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
9 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
10 A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding Completed NCT01112852 Phase 4 pantoloc 40 mg;somatostatin or terlipressin
11 Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study Recruiting NCT03624517 Phase 4 Octreotide
12 Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Recruiting NCT01970748 Phase 4 Propranolol
13 Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed: A Randomized Controlled Study Not yet recruiting NCT05199038 Phase 4 Octreotide
14 Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices Unknown status NCT01897051 Phase 2, Phase 3 Rifaximin + propranolol;Propranolol + Placebo
15 Effect of Administration "Add on" of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol Unknown status NCT02508623 Phase 3 Rifaximin;Placebo
16 Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices Unknown status NCT03388125 Phase 3 Injection Sclerotherapy;N-butyl-2-cyanoacrylate
17 A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy Unknown status NCT01618890 Phase 3
18 Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT) and Cavernous Transformation of the Portal Vein (CTPV) Unknown status NCT02853526 Phase 3 Propranolol;Warfarin
19 Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices Completed NCT00493480 Phase 3 carvedilol;propranolol
20 Prospective Randomized Study on the Efficacy of Endoscopic Injection Therapy With Fibrin Sealant Versus Endoscopic Ligature for Acute Hemostasis and the Prophylaxis of Recurrent Bleeding From Esophageal Varices Completed NCT00161915 Phase 3 Fibrin Sealant
21 Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
22 The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension Completed NCT00331188 Phase 3 Sanvar® (vapreotide)
23 A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding Completed NCT01095185 Phase 3 Simvastatin;Placebo
24 Esophageal Stent is More Effective Than Tamponade Controlling Refractory Esophageal Variceal Bleeding: a Randomized Controlled Trial Completed NCT01242280 Phase 3
25 A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis Recruiting NCT04365868 Phase 2, Phase 3 belapectin;Placebo
26 Randomized Controlled Trial of Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding in Cirrhotic Patients With Arterial Hypertension Recruiting NCT04499898 Phase 2, Phase 3 Carvedilol
27 Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding Terminated NCT00409084 Phase 3
28 Randomized Study Comparing Ligation With Propranolol for Primary Prophylaxis of Variceal Bleeding in Candidates for Liver Transplantation Terminated NCT00337740 Phase 3 propranolol
29 A New Technique to Enhance Detection of Small Esophageal Varices by PillCam ESO Capsule Endoscopy Withdrawn NCT00911131 Phase 3
30 Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis Completed NCT01188733 Phase 1, Phase 2 Long acting octreotide 10mg;Long acting Octreotide 30mg;Saline
31 Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy Completed NCT01851252 Phase 1
32 Predictive Factors and Outcome of Esophageal Ulcers After Endoscopic Treatment of Esophageal Varices; Multicenter Study Unknown status NCT02256046
33 Magnetic-assisted Capsule Endoscope System With or Without 3D Images in Esophageal Varices Detection Compared With Conventional Esophagogastroduodenoscopy in Cirrhotic Patients Unknown status NCT04588974
34 A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis Unknown status NCT01212250 carvedilol;Placebo
35 Optimal Time for Follow up After Variceal Band Ligation in Cirrhotic Patients: a Randomized Trial Unknown status NCT04602663
36 A Single-center Randomized Controlled Study of Secondary Prophylaxis of Cirrhosis Related Esophagogastric Variceal Hemorrhage Treated With HVPG-guided Therapy or Standard Esophageal Variceal Ligation Plus Beta-blocker Unknown status NCT03687216
37 Evaluation of Gastroesophageal Varices in Cirrhotic and Non-cirrhotic Patients With Portal Hypertension by Transnasal Endoscopy. Unknown status NCT02767206
38 Evaluation of Blood Ammonia Level as a Non Invasive Predictor for Presence of Gastroesophageal Varices and Risk of Bleeding Unknown status NCT03212872
39 Investigator Sponsored Study of Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices Unknown status NCT01426087 Somatostatin
40 Efficacy of Nonselective Beta Blockers vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices Completed NCT02583698 Carvedilol;Placebo
41 Early Primary Prophylaxis With Beta-Blockers In Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: A Randomized Controlled Trial Completed NCT00772057 Propranolol;Placebo
42 Development and Validation of an Noninvasive Model for Predicting High Risk Esophageal Varices in Cirrhosis Completed NCT04210297
43 San Diego Bleeding Esophageal Varices Study Completed NCT00690027
44 Evaluation of the PillCam™ Eso Capsule in the Detection of Esophageal Varices Completed NCT00481416
45 Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study Completed NCT02593799
46 A Prospective Randomized Study to Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices Completed NCT02465645 Carvedilol;Carvedilol + Simvastatin
47 The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study Completed NCT03583996
48 Transparent Cap-assisted Endoscopic Sclerotherapy(Lauromacrogol Injection) in Esophageal Varices: a Randomized Controlled Trial Completed NCT02361593
49 Noninvasive Tests to Predict the Presence of Esophageal Varices in Patients With Liver Cirrhosis Completed NCT03513887
50 A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Early Primary Prophylaxis of Esophageal Varices in Cirrhosis. Completed NCT01196507 Carvedilol;Placebo

Search NIH Clinical Center for Esophageal Varix

Genetic Tests for Esophageal Varix

Genetic tests related to Esophageal Varix:

# Genetic test Affiliating Genes
1 Esophageal Varix 28

Anatomical Context for Esophageal Varix

Organs/tissues related to Esophageal Varix:

MalaCards : Liver, Spleen, Kidney, Heart, Colon, Spinal Cord, Bone Marrow

Publications for Esophageal Varix

Articles related to Esophageal Varix:

(show top 50) (show all 7071)
# Title Authors PMID Year
1
Comparison of liver biopsy and transient elastography based on clinical relevance. 53 62
18818788 2008
2
[Splanchnic hemodynamic effects of somatostatin and octreotide in cirrhotic patients. A Doppler ultrasonographic study]. 53 62
19025306 2008
3
Somatostatin analogues for acute bleeding oesophageal varices. 53 62
18677774 2008
4
Right liver lobe/albumin ratio: contribution to non-invasive assessment of portal hypertension. 53 62
17879402 2007
5
[Non-endoscopic predictors of large esophageal varices in patients with liver cirrhosis]. 53 62
17641556 2007
6
Coagulation abnormalities in cirrhotic patients with portal vein thrombosis. 53 62
18257465 2007
7
[Bleeding oesophageal varices--therapeutic options]. 53 62
17633875 2007
8
[The value of Doppler-ultrasonography and laboratory tests as non-invasive predictors of the presence of esophageal varices in patients with chronic liver disease]. 53 62
17047433 2006
9
[Non-invasive diagnosis of portal hypertension in cirrhosis. Application to the primary prevention of varices]. 53 62
16435503 2005
10
Review: somatostatin and its analogues do not reduce mortality in acute bleeding esophageal varices. 53 62
15989304 2005
11
Best evidence topic report. Terlipressin or somatostatin for the treatment of bleeding oesophageal varices. 53 62
15911952 2005
12
Somatostatin analogues for acute bleeding oesophageal varices. 53 62
15674868 2005
13
Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?[ISRCTN63456799]. 53 62
15596012 2004
14
Earlier recurrence of esophageal varices, following therapy, in patients with primary biliary cirrhosis (PBC) compared with non-PBC patients. 53 62
15580402 2004
15
Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices. 53 62
15077917 2004
16
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. 53 62
14752839 2004
17
Two findings of portal hypertension: evaluation of correlation between serum-ascites albumin gradient and esophageal varices in non-alcoholic cirrhosis. 53 62
15048594 2003
18
[Vasoconstrictive Therapies for Bleeding Esophageal Varices and their Mechanisms of Action]. 53 62
14562199 2003
19
Lower levels of the circulating neuropeptide somatostatin in Schistosoma mansoni infected patients may have pathological significance. 53 62
12535248 2003
20
Review: Somatostatin analogues reduce blood products used in acute bleeding esophageal varices but do not reduce mortality. 53 62
12418833 2002
21
Somatostatin analogues for acute bleeding oesophageal varices. 53 62
11869569 2002
22
Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. 53 62
12483269 2002
23
Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. 53 62
12522534 2002
24
Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. 53 62
11443618 2001
25
Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? 53 62
11172334 2001
26
[Drug therapy of hemorrhage in esophageal and gastric varices: role of vasoactive drugs]. 53 62
11291271 2000
27
[Sclerotherapy versus somatostatin in the treatment of upper digestive hemorrhage caused by rupture of esophageal varices]. 53 62
11236267 2000
28
Surgical indications for advanced hepatocellular carcinoma. 53 62
11020886 2000
29
Somatostatin or octreotide for acute bleeding oesophageal varices. 53 62
10796699 2000
30
Two different doses and duration schedules of somatostatin -14 in the treatment of patients with bleeding oesophageal varices: a non-randomised controlled study. 53 62
10673084 2000
31
Non-invasive diagnosis of esophageal varices in chronic liver diseases. 53 62
10580584 1999
32
Octreotide and bleeding oesophageal varices: new indication. Nothing new. 53 62
11503829 1999
33
Resource analysis of somatostatin in the treatment of bleeding esophageal varices. 53 62
10567787 1999
34
Somatostatin or octreotide in acute variceal bleeding. 53 62
10207229 1999
35
Benefit of prophylactic endoscopic sclerotherapy of esophageal varices. A retrospective analysis. 53 62
9602001 1998
36
Approach to the management of bleeding esophageal varices: role of somatostatin. 53 62
9603441 1998
37
Development of analogues: successes and failures. 53 62
9595598 1998
38
[Gastroenterology. I: General gastroenterology]. 53 62
9499375 1997
39
Cirrhosis: a new, but expected cause of biliary sludge. 53 62
9046383 1997
40
[Molecular biology, pharmacology and signal transduction of 5 cloned human somatostatin receptors]. 53 62
9045539 1996
41
Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. 53 62
8912146 1996
42
Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices--final report of a placebo-controlled, double-blind study. 53 62
8921578 1996
43
Survival in alcoholic liver cirrhosis: prognostic value of portal pressure, size of esophageal varices and biochemical data. Comparison with Child classification. 53 62
8776835 1996
44
Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? 53 62
8693420 1996
45
Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. 53 62
8621142 1996
46
[Randomized trial and meta-analysis of somatostatin versus placebo in bleeding esophageal varices]. 53 62
8685994 1996
47
Somatostatin in bleeding oesophageal varices. Important information about trial was omitted. 53 62
8601127 1996
48
[Drug therapy of acute esophageal varices bleeding (vasopressin, terlipressin, somatostatin)]. 53 62
8571017 1995
49
A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. 53 62
7557097 1995
50
Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. 53 62
7787594 1995

Variations for Esophageal Varix

Expression for Esophageal Varix

Search GEO for disease gene expression data for Esophageal Varix.

Pathways for Esophageal Varix

Pathways related to Esophageal Varix according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.86 THPO SERPINC1 SERPINA1 LGALS3BP F3 F2
2
Show member pathways
12.08 SERPINC1 SERPINA1 F3 F2
3 11.68 THPO SERPINA1 INS ALB AFP
4
Show member pathways
11.47 SERPINC1 SERPINA1 F2 CP ALB AFP
5
Show member pathways
10.89 INS F2 ALB AFP

GO Terms for Esophageal Varix

Cellular components related to Esophageal Varix according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.12 AFP ALB CP CRP F2 F3
2 collagen-containing extracellular matrix GO:0062023 10.1 SERPINC1 SERPINA1 LGALS3BP LGALS3 F3 F2
3 endoplasmic reticulum lumen GO:0005788 10.1 SERPINC1 SERPINA1 INS F2 CP ALB
4 blood microparticle GO:0072562 9.93 ALB CP F2 HP LGALS3BP SERPINC1
5 extracellular space GO:0005615 9.84 AFP ALB ATP4A CP CRP F2

Biological processes related to Esophageal Varix according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.76 SERPINC1 SERPINA1 F3 F2
2 acute-phase response GO:0006953 9.32 SERPINA1 INS HP F2 CRP
3 hemostasis GO:0007599 9.26 SERPINC1 SERPINA1 F3 F2

Molecular functions related to Esophageal Varix according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.76 SERPINC1 SERPINA1 INS F3
2 P-type sodium:potassium-exchanging transporter activity GO:0005391 9.56 ATP4A ATP12A
3 P-type potassium transmembrane transporter activity GO:0008556 8.96 ATP4A ATP12A
4 P-type potassium:proton transporter activity GO:0008900 8.92 ATP4A ATP12A

Sources for Esophageal Varix

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....